Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death.
Despite tremendous progress in diagnosis and therapeutic strategies and significant …

Simple Summary Cancer metastasis is often associated with a dismal prognosis for the
patient. It is, therefore, crucial to understand the mechanisms behind the cascade of events …

Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …

Met tyrosine kinase, a receptor for a hepatocyte growth factor (HGF), plays a critical role in
tumor growth, metastasis, and drug resistance. Mitochondria are highly dynamic and …

Colorectal cancer (CRC), a leading cause of cancer-related mortalities globally, results from
the accumulation of multiple genetic and epigenetic alterations in the normal colonic and …

Cancer is highly infiltrated by myeloid-derived suppressor cells (MDSCs). Currently
available immunotherapies do not completely eradicate MDSCs. Through a genome-wide …

MET alterations have been validated as a driven factor in NSCLC and gastric cancers. The c-
Met inhibitors, capmatinib, tepotinib, and savolitinib, are only approved for the treatment of …

Simple Summary The progression of liver tumors is highly influenced by the interactions
between cancer cells and the surrounding environment, and, consequently, can determine …

Background Epidermal growth factor receptor (EGFR) is an essential target for cancer
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …